Athersys, Inc. (ATHX) EVP Sells $12,600.00 in Stock

Athersys, Inc. (NASDAQ:ATHX) EVP John J. Harrington sold 7,500 shares of the company’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $1.68, for a total value of $12,600.00. Following the transaction, the executive vice president now directly owns 658,474 shares of the company’s stock, valued at $1,106,236.32. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Shares of Athersys, Inc. (NASDAQ:ATHX) traded up $0.03 during mid-day trading on Friday, hitting $1.90. The stock had a trading volume of 400,728 shares, compared to its average volume of 1,013,668. Athersys, Inc. has a twelve month low of $1.02 and a twelve month high of $2.63.

Several hedge funds have recently made changes to their positions in ATHX. Bank of America Corp DE raised its stake in shares of Athersys by 17.2% during the 1st quarter. Bank of America Corp DE now owns 61,580 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 9,019 shares during the period. SG Americas Securities LLC raised its stake in shares of Athersys by 329.7% during the 2nd quarter. SG Americas Securities LLC now owns 73,434 shares of the biopharmaceutical company’s stock worth $111,000 after buying an additional 56,345 shares during the period. State of Wisconsin Investment Board acquired a new position in shares of Athersys during the 2nd quarter worth approximately $113,000. Blair William & Co. IL raised its stake in shares of Athersys by 708.0% during the 2nd quarter. Blair William & Co. IL now owns 80,804 shares of the biopharmaceutical company’s stock worth $122,000 after buying an additional 70,804 shares during the period. Finally, Thompson Davis & CO. Inc. raised its stake in Athersys by 743.9% in the 3rd quarter. Thompson Davis & CO. Inc. now owns 64,303 shares of the biopharmaceutical company’s stock valued at $132,000 after purchasing an additional 56,683 shares during the last quarter. 21.01% of the stock is owned by institutional investors and hedge funds.

Several research analysts have recently weighed in on ATHX shares. ValuEngine downgraded Athersys from a “hold” rating to a “sell” rating in a research note on Tuesday, December 5th. Maxim Group set a $12.00 target price on Athersys and gave the stock a “buy” rating in a research note on Thursday, October 5th. Finally, Zacks Investment Research raised Athersys from a “hold” rating to a “buy” rating and set a $2.25 target price for the company in a research note on Thursday, September 7th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. Athersys currently has a consensus rating of “Hold” and a consensus price target of $7.17.

COPYRIGHT VIOLATION WARNING: “Athersys, Inc. (ATHX) EVP Sells $12,600.00 in Stock” was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://www.com-unik.info/2017/12/22/athersys-inc-athx-evp-sells-12600-00-in-stock.html.

Athersys Company Profile

Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.

Insider Buying and Selling by Quarter for Athersys (NASDAQ:ATHX)

Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit